Opko Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost bought 1,800 shares of the company’s stock in a transaction that occurred on Monday, June 26th. The shares were bought at an average price of $6.97 per share, for a total transaction of $12,546.00. Following the transaction, the chief executive officer now directly owns 3,068,951 shares in the company, valued at $21,390,588.47. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Thursday, June 22nd, Phillip Md Et Al Frost bought 131,000 shares of Opko Health stock. The shares were bought at an average price of $6.72 per share, for a total transaction of $880,320.00.
  • On Thursday, June 15th, Phillip Md Et Al Frost bought 200,000 shares of Opko Health stock. The shares were bought at an average price of $6.43 per share, for a total transaction of $1,286,000.00.
  • On Tuesday, June 13th, Phillip Md Et Al Frost bought 7,200 shares of Opko Health stock. The shares were bought at an average price of $6.51 per share, for a total transaction of $46,872.00.
  • On Monday, June 12th, Phillip Md Et Al Frost bought 1,800 shares of Opko Health stock. The shares were bought at an average price of $6.37 per share, for a total transaction of $11,466.00.
  • On Friday, June 9th, Phillip Md Et Al Frost bought 25,000 shares of Opko Health stock. The shares were bought at an average price of $6.39 per share, for a total transaction of $159,750.00.
  • On Wednesday, June 7th, Phillip Md Et Al Frost bought 55,600 shares of Opko Health stock. The shares were bought at an average price of $6.27 per share, for a total transaction of $348,612.00.
  • On Tuesday, June 6th, Phillip Md Et Al Frost bought 30,000 shares of Opko Health stock. The shares were bought at an average price of $6.30 per share, for a total transaction of $189,000.00.
  • On Monday, June 5th, Phillip Md Et Al Frost bought 55,000 shares of Opko Health stock. The shares were bought at an average price of $6.31 per share, for a total transaction of $347,050.00.
  • On Wednesday, May 31st, Phillip Md Et Al Frost bought 207,700 shares of Opko Health stock. The shares were bought at an average price of $6.11 per share, for a total transaction of $1,269,047.00.
  • On Tuesday, May 30th, Phillip Md Et Al Frost bought 18,600 shares of Opko Health stock. The shares were bought at an average price of $6.28 per share, for a total transaction of $116,808.00.

Opko Health, Inc. (NASDAQ:OPK) opened at 7.10 on Tuesday. Opko Health, Inc. has a 12-month low of $5.99 and a 12-month high of $12.15. The firm’s market cap is $3.97 billion. The firm’s 50-day moving average is $6.70 and its 200 day moving average is $8.27.

Opko Health (NASDAQ:OPK) last announced its earnings results on Tuesday, May 9th. The biotechnology company reported ($0.06) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.04) by $0.02. Opko Health had a negative net margin of 3.60% and a negative return on equity of 2.13%. The business had revenue of $296.10 million for the quarter, compared to the consensus estimate of $313.36 million. During the same quarter last year, the firm posted ($0.02) EPS. The business’s quarterly revenue was up 1.8% on a year-over-year basis. Equities analysts forecast that Opko Health, Inc. will post ($0.20) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Opko Health, Inc. (OPK) CEO Phillip Md Et Al Frost Purchases 1,800 Shares” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US and international copyright legislation. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/06/27/opko-health-inc-opk-ceo-phillip-md-et-al-frost-purchases-1800-shares.html.

Several hedge funds have recently made changes to their positions in OPK. AQR Capital Management LLC acquired a new stake in shares of Opko Health during the fourth quarter worth approximately $105,000. Timber Hill LLC acquired a new stake in shares of Opko Health during the first quarter worth approximately $114,000. Comerica Bank acquired a new stake in shares of Opko Health during the fourth quarter worth approximately $117,000. World Asset Management Inc boosted its stake in shares of Opko Health by 23.6% in the first quarter. World Asset Management Inc now owns 15,176 shares of the biotechnology company’s stock worth $121,000 after buying an additional 2,900 shares during the period. Finally, IFC Holdings Incorporated FL boosted its stake in shares of Opko Health by 15.9% in the first quarter. IFC Holdings Incorporated FL now owns 15,339 shares of the biotechnology company’s stock worth $122,000 after buying an additional 2,100 shares during the period. Hedge funds and other institutional investors own 23.65% of the company’s stock.

A number of research analysts recently issued reports on OPK shares. Zacks Investment Research downgraded shares of Opko Health from a “hold” rating to a “sell” rating in a research report on Friday, March 3rd. Ladenburg Thalmann Financial Services reiterated a “buy” rating and set a $19.50 target price on shares of Opko Health in a research report on Friday, June 16th. Guggenheim started coverage on shares of Opko Health in a research report on Tuesday, March 14th. They set a “buy” rating and a $25.00 target price on the stock. Jefferies Group LLC dropped their target price on shares of Opko Health from $10.00 to $8.00 and set a “hold” rating on the stock in a research report on Thursday, March 2nd. Finally, Standpoint Research reiterated a “buy” rating and set a $14.00 target price on shares of Opko Health in a research report on Sunday, March 5th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $16.58.

Opko Health Company Profile

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.